FDA approves new Alzheimer’s drug that appears to slow the disease
He Food and Drug Administration on Friday approved an Alzheimer's drug that has been shown in clinical trials to slow cognitive decline in patients in the early stages of the disease.The approval offers patients renewed hope after repeated failures to find effective treatments, even though there have been reports of side effects with the new drug, experts say. The drug, lecanemab, which will be sold under the name Leqembi, is an infusion of monoclonal antibodies given every two weeks.The FDA approved Leqembi for use in people with mild cognitive impairment or early Alzheimer's disease.The drug was approved in a fast…
